Lineage Therap share price logo

Lineage Therap

AMEX: LCTX

$0.82

+0.02

(+2.60%)

as on

Lineage Therap Stock Performance

as on November 18, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $0.77
    $0.88
    downward going graph

    5.61%

    Downside

    7.87%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.77
    $1.99
    downward going graph

    5.61%

    Downside

    143.32%

    Upside

    downward going graph

Lineage Therap share price movements today

Previous Close
$0.80
Open
$0.82
Volume
6.1M
Market Cap
$231.4M
Day's Low - High
$0.77 - $0.88
52 Week Low - High
$0.77 - $1.99

Lineage Therap Historical Returns

1 Month Return
-18.73 %
3 Month Return
-24.99 %
1 Year Return
-54.3 %
3 Year Return
-16.31 %
5 Year Return
-66.59 %

Lineage Therap Stock Fundamentals & Key Indicators

Check Lineage Therap market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$231.4M

EPS (TTM)

0.0065

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

140.71

Industry PE ratio

-2.76

PEG Ratio

0.65

EBITDA

-2.2M

Revenue (TTM)

10.8M

Profit Margin

95.88%

Return On Equity TTM

3.10%

Lineage Therap vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lineage Therap with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$231.4M-66.59%140.7195.88%0.00%
Neutral$100.6B0.07%-35.1828.00%0.00%
StrongBuy$47.6BNA67.0788.39%0.00%
StrongBuy$136.6B185.68%34.3985.57%0.00%
Buy$98.8B48.39%20.3585.77%0.39%

Stock Returns calculator for Lineage Therap Stock including INR - Dollar returns

The Lineage Therap stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Lineage Therap investment value today

Current value as on today

₹49,437

Returns

-₹50,563

(-50.56%)

Returns from Lineage Therap Stock

-₹53,115 (-53.11%)

Dollar Impact

₹2,552 (+2.55%)

Analyst Recommendation on Lineage Therap Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Lineage Therap. Average target price of $5.5

Lineage Therap Share Price Target

Get share price movements and forecasts by analysts on Lineage Therap.

What analysts predicted

85.17%UPSIDE

Target Price

$5.5

Current Price

$0.8158

Analyzed by

2 Analysts

High

$9

Target

$5.50

Low

$4

Lineage Therap target price $5.5, a slight upside of 85.17% compared to current price of $0.8158. According to 2 analysts rating.

Lineage Therap Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
1
3
2
1
2
3
6
1
1
1
Gross Profit
1
3
2
1
2
3
6
1
0
1
Operating Income
-5
-3
-5
-6
-19
-3
-6
-7
-8
-7
EBITDA
-5
-2
-3
-3
-4
-29
-4
-4
1
4
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-5
-3
-3
-4
-30
-29
-4
-4
1
4
Income Tax Expense
-
-
-
-
-
-
-5
-
-
0
Net Income
-5
-3
-3
-4
-30
-29
0
-4
1
4
Net Profit Margin
96.88%
98.99%
94.63%
97.60%
98.59%
99.86%
99.00%
89.10%
82.51%
99.65%

Lineage Therap Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
1
0
3
14
8
9
14
Gross Profit
1
1
1
0
2
13
8
9
13
Operating Income
-38
-41
-38
-26
-49
-22
-24
-21
-21
EBITDA
-37
-37
-35
-24
-42
-25
-22
-17
-67
Interest Expense
0
10
-
-
-
-
-
-
-
Depreciation
3
3
3
2
0
0
0
0
0
Income Before Tax
-23
-47
-19
-21
-43
-25
-23
-18
-68
Income Tax Expense
-
0
-7
-1
-
0
-1
-
-5
Net Income
-19
-45
-11
-20
-43
-26
-21
-18
-63
Net Profit Margin
90.63%
78.67%
72.12%
50.19%
63.40%
95.05%
92.50%
96.48%
94.19%

Lineage Therap Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-5
-3
-3
-4
-30
-29
0
-4
1
4
Operating Cash Flow
-5
-5
-6
-4
-5
-3
-4
-8
-7
-5
Investing Cash Flow
-8
3
2
1
0
0
-15
-2
3
-5
Financing Cash Flow
0
0
21
5
0
1
20
5
4
0
Change in Cash
-13
-1
18
1
-5
-1
0
-4
1
-10

Lineage Therap Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-23
-46
-11
-20
-43
-26
-21
-18
-63
Operating Cash Flow
-30
-30
-31
-19
-23
1
-28
-23
-18
Investing Cash Flow
-10
11
16
13
9
-46
46
-2
-13
Financing Cash Flow
55
5
0
29
36
1
6
35
26
Change in Cash
14
-13
-14
23
23
-44
24
10
-5

Global Institutional Holdings in Lineage Therap

Check out the Institutions with significant holdings in Lineage Therap.

Funds
Holdings
Neal Bradsher
13.48%
BlackRock, Inc.
5.48%
Vanguard
3.91%
VANGUARD INDEX FUNDS
3.51%
iShares
3.25%

Lineage Therap News & Key Events

  • img

    Today's Timeline - 12 November

    Fri, 03:15 AM

    -

    Lineage Cell Therapeutics acquires NeuroAirmid, adding HUNT1 neural cell therapy for Huntington's disease to its pipeline.

Insights on Lineage Therap

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.06M → 1.43M (in $), with an average increase of 25.5% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -4.81M → 4.23M (in $), with an average increase of 244.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 181.6% return, outperforming this stock by 197.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 763.8% return, outperforming this stock by 818.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, LCTX stock has moved down by -28.4%

About Lineage Therap

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
OrganisationLineage Therap
Headquarters2173 Salk Avenue, Carlsbad, CA, 92008, US
IndustryBiotechnology
CEOBrian Culley

Key Management of Lineage Therap

Name

Title

Dr. Rami Skaliter M.Sc., Ph.D.

Chief Executive Officer of Cell Cure Neurosciences

Ms. Alexandra Hernandez

Senior Director of Finance & Controller

Mr. Brian M. Culley M.A., M.B.A.

CEO, President & Director

Ms. Jill Ann Howe

Chief Financial Officer

Dr. Priyantha Herath M.D., Ph.D.

Senior VP & Head of Clinical Operations

Dr. Harold D. Waitz Ph.D.

Vice President of Regulatory Affairs & Quality Control

Mr. George A. Samuel III, J.D.

General Counsel & Company Secretary

Ms. Ioana C. Hone

Director of Investor Relations

Dr. Charlotte Hubbert Ph.D.

Vice President of Corporate Strategy & Development

FAQs

What is Lineage Therap share price today?

Lineage Therap share price today is $0.82 as on at the close of the market. Lineage Therap share today touched a day high of $0.88 and a low of $0.77.

What is the 52 week high and 52 week low for Lineage Therap share?

Lineage Therap share touched a 52 week high of $1.99 on and a 52 week low of $0.77 on . Lineage Therap stock price today i.e. is closed at $0.82,which is 58.90% down from its 52 week high and 5.95% up from its 52 week low.

What is Lineage Therap's market capitalisation today?

Lineage Therap market capitalisation is $0.00T as on .

How to invest in Lineage Therap Stock (LCTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lineage Therap on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Lineage Therap Stock (LCTX) from India?

Indian investors can start investing in Lineage Therap (LCTX) shares with as little as ₹93.459999084473 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹934.60 in Lineage Therap stock (as per the Rupee-Dollar exchange rate as on ). Based on Lineage Therap share’s latest price of $0.82 as on November 18, 2026 at 8:46 am IST, you will get 12.2579 shares of Lineage Therap. Learn more about fractional shares .

What are the returns that Lineage Therap has given to Indian investors in the last 5 years?

Lineage Therap stock has given -66.59% share price returns and 26.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?